<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03768128</url>
  </required_header>
  <id_info>
    <org_study_id>16-4049-12</org_study_id>
    <nct_id>NCT03768128</nct_id>
  </id_info>
  <brief_title>Safety and Performance of the Journey™ II UNI Unicompartmental Knee System</brief_title>
  <acronym>JII-Uni</acronym>
  <official_title>A Prospective, Multicenter Post-Market Clinical Follow-up Study to Evaluate the Safety and Performance of the Journey™ II UNI Unicompartmental Knee System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will evaluate the early to midterm safety and performance of the JOURNEY™
      II UNI UKS in patients with non-inflammatory degenerative joint disease of the knee requiring
      lateral or medial knee compartment replacement. Clinical, radiographic, health economic and
      safety outcomes will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and performance of the JOURNEY™ II UNI UKS in patients with
      unicompartmental degeneration of the knee by demonstrating non-inferiority of the cumulative
      percent implant survival in subjects with the JOURNEY™ II UNI UKS implanted, compared to a
      literature reference rate of 91.7% (AOA annual report 2015)12 at 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Implant survival 5 years postoperatively</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device-related adverse events</measure>
    <time_frame>5 year</time_frame>
    <description>All AEs will be collected and reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic assessments</measure>
    <time_frame>5 year</time_frame>
    <description>To assess changes in implant fixation and bone integrity, an evaluation will be performed based upon comparison of Antero posterior and Lateral radiographs over multiple time-points. Radiographs will be also evaluated for radiolucencies, osteolysis, implant positioning, implant migration, implant loosening, periprosthetic fracture, wear of the articulating surfaces of replacement components</description>
  </secondary_outcome>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Non-inflammatory Degenerative Joint Disease (NIDJD) of the Knee</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Journey™ II UNI Unicompartmental Knee System</intervention_name>
    <description>Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.
It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        JOURNEY™ II UNI Unicompartmental Knee System (UKS) in patients with non-inflammatory
        degenerative joint disease (NIDJD) of the knee requiring either medial or lateral
        compartment knee replacement.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet all of the following criteria for inclusion in the study.

               1. Unicompartmental, NIDJD, including OA, traumatic arthritis, or avascular
                  necrosis.

               2. Eighteen (18) years of age or older at the time of surgery.

               3. Skeletally mature in the judgement of the PI.

               4. Has met an acceptable preoperative medical clearance and is free of (or
                  acceptably managed) cardiac, pulmonary, hematological, infection, or other
                  conditions that would pose an excessive operative risk.

               5. Willing and able to participate in required follow-up visits at the
                  investigational site and to complete study procedures and questionnaires.

               6. Consented to participate in the study by signing the EC-approved ICF.

                  Exclusion Criteria:

          -  Subjects meeting any of the following criteria must be excluded from participation in
             the study.

               1. Correction of functional deformity.

               2. Revision procedures where other treatments or devices have failed.

               3. Treatment of fractures that are unmanageable using other techniques.

               4. Inadequate bone stock to support the device which would make the procedure
                  unjustifiable, including but not limited to severe osteopenia/osteoporosis or
                  family history of severe osteoporosis/osteopenia.

               5. Body Mass Index (BMI) &gt; 40.

               6. Collateral ligament insufficiency.

               7. Active infection, treated or untreated, systemic or at the site of the planned
                  surgery or previous intra-articular infections.

               8. Incomplete or deficient soft tissue surrounding the knee.

               9. Conditions that may interfere with the UKA survival or outcome, including but not
                  limited to Paget's disease, Charcot disease, vascular insufficiency, muscular
                  atrophy, uncontrolled diabetes, renal insufficiency or neuromuscular disease.

              10. Diagnosis of an immunosuppressive disorder.

              11. Known allergy to study device or one or more of its components.

              12. Pregnant or planning to become pregnant during the course of the study.

              13. Subject, in the opinion of the PI, has an emotional or neurological condition
                  that would pre-empt their ability or willingness to participate in the study
                  including mental illness, mental retardation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Christine Mallaroni</last_name>
    <role>Study Chair</role>
    <affiliation>Smith &amp; Nephew, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Christine Mallaroni, CSM</last_name>
    <phone>+33 (0)6 77 64 03 41</phone>
    <email>MarieChristine.MALLARONI@smith-nephew.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jomary Santana</last_name>
      <phone>312-432-2429</phone>
      <email>jomary.santana@rushortho.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Murray</last_name>
      <email>kelly.murray@rushortho.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tad Gerlinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OrthoIllinois, LTD</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Rundall</last_name>
      <phone>815-381-7468</phone>
      <email>heatherr@othoillinois.com</email>
    </contact>
    <investigator>
      <last_name>Victor Antonacci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Chmell</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poliambulanza Institute Hospital Foundation</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianmarco Regazzola</last_name>
      <phone>0303515718</phone>
      <email>dot.segreteria@poliambulanza.it</email>
    </contact>
    <investigator>
      <last_name>Flavio Terragnoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gianmarco Regazzola</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Villa Aprica</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariolina Nughes</last_name>
      <phone>+39 335269769</phone>
      <email>info@corradobait.com</email>
    </contact>
    <investigator>
      <last_name>Corrado Bait</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Giardella</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capitanio Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Zeromski Hospital</name>
      <address>
        <city>Kraków</city>
        <zip>31-913</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Dutka</last_name>
      <phone>503 198 460</phone>
      <email>jdorttra@interia.pl</email>
    </contact>
    <investigator>
      <last_name>Julian Dutka</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Łukasz Dutka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafał Musiałek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominik Kostarcyzyk</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maciej Pawlucki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Miejski Zabrze</name>
      <address>
        <city>Zabrze</city>
        <zip>41-803</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urszula Ślęzak</last_name>
      <phone>+48601235093</phone>
      <email>urszulaslezak@op.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Hawranek</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grzegorz Wrzask</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 27, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

